Lumasiran is a subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). Where it is approved, it is marketed as OXLUMO™ (lumasiran).
To be eligible to seek access to lumasiran through the early access program (EAP), participants must meet certain requirements, including, but not limited to:
Only a licensed physician can request lumasiran. If you are a patient living in a country where lumasiran is not commercially available and are interested in seeking access to lumasiran through the early access program, please speak to your physician. Alnylam can only respond to a physician requesting access to lumasiran on behalf of a patient in his/her care.
If you are a physician who is seeking to obtain access to lumasiran for a patient in your care, please contact eap@alnylam.com
If you are a physician or patient and have a medical question, please contact medinfo@alnylam.com.